Healthcare -
Biotechnology - NASDAQ - US
$ 1.98
-2.94 %
$ 661 M
Market Cap
-1.62
P/E
1. INTRINSIC VALUE
Balance Sheet
Iovance Biotherapeutics, Inc.
| Current Assets | 457 M |
| Cash & Short-Term Investments | 324 M |
| Receivables | 69.3 M |
| Other Current Assets | 63.9 M |
| Non-Current Assets | 453 M |
| Long-Term Investments | 0 |
| PP&E | 164 M |
| Other Non-Current Assets | 289 M |
| Current Liabilities | 122 M |
| Accounts Payable | 27.5 M |
| Short-Term Debt | 12.9 M |
| Other Current Liabilities | 81.9 M |
| Non-Current Liabilities | 77.7 M |
| Long-Term Debt | 45.4 M |
| Other Non-Current Liabilities | 32.3 M |
EFFICIENCY
Earnings Waterfall
Iovance Biotherapeutics, Inc.
| Revenue | 164 M |
| Cost Of Revenue | 124 M |
| Gross Profit | 40.1 M |
| Operating Expenses | 435 M |
| Operating Income | -395 M |
| Other Expenses | -23.1 M |
| Net Income | -372 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Iovance Biotherapeutics, Inc.
| Net Income | -372 M |
| Depreciation & Amortization | 31.6 M |
| Capital Expenditures | -11.1 M |
| Stock-Based Compensation | 110 M |
| Change in Working Capital | -123 M |
| Others | -5.61 M |
| Free Cash Flow | -364 M |
Wall Street Analysts Price Targets
Iovance Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for IOVA of $12.8 , with forecasts ranging from
a
low of
$2 to a high of $24 .
IOVA Lowest Price Target
Wall Street Target
2 USD
1.01%
IOVA Average Price Target
Wall Street Target
12.8 USD
545.74%
IOVA Highest Price Target
Wall Street Target
24 USD
1112.12%
4. DIVIDEND
ANALYSIS
IOVA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Iovance Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
503 K USD 1
9-12 MONTHS
0 USD 0
Bought
107 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , June 20, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit.
prnewswire.com
- 1 week ago
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
globenewswire.com
- 1 week ago
Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
prnewswire.com
- 1 week ago
IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
globenewswire.com
- 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA
NEW YORK , June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025.
prnewswire.com
- 1 week ago
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
NEW YORK , June 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline. So What: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
prnewswire.com
- 1 week ago
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) and certain of its officers.
globenewswire.com
- 1 week ago
Contact The Gross Law Firm by July 14, 2025 Deadline to Join Class Action Against Iovance Biotherapeutics, Inc.(IOVA)
NEW YORK , June 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
prnewswire.com
- 1 week ago
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman
SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.
globenewswire.com
- 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
globenewswire.com
- 2 weeks ago
IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
globenewswire.com
- 2 weeks ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options
globenewswire.com
- 2 weeks ago
8. Profile
Summary
Iovance Biotherapeutics, Inc. IOVA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 661 M
Dividend Yield
0.00%
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Contact
825 Industrial Road, San Carlos, CA, 94070
https://www.iovance.com
IPO
Date
Oct. 15, 2010
Employees
838
Officers
Dr. Igor P. Bilinsky Ph.D.
Chief Operating Officer
Ms. Sara Pellegrino
Senior Vice President of Investor Relations & Corporate Communications
Ms. Tracy Winton
Executive Vice President of Human Resources
Dr. Friedrich Graf Finckenstein M.D.
Chief Medical Officer
Dr. Raj K. Puri M.D., Ph.D.
Chief Regulatory Officer
Mr. Howard B. Johnson M.B.A.
Chief Business Officer
Mr. Kevin Smyth
Executive Vice President of Quality
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director
Mr. Jean-Marc Bellemin M.B.A.
Chief Financial Officer, Principal Accounting Officer & Treasurer
Mr. Brian Shew M.B.A.
Senior Vice President & Head of Digital and Information Technology